Seed & Series A in Denmark

01/12/2025

Financing a Danish Biotech company has apparently never been more challenging. Based on feedback from partnering meetings in 2025 it seems that raising Series A financing has become an unprecedented challenge. However, when looking at the available data on the...

Treetop Meeting

27/08/2025

We usually do not share updates from internal meetings – but this was too fantastic not to share. A full day meeting in the midst of branches of +100 year old oaks and beech trees overlooking Isefjorden in “the treetop huts” at Ryegaard & Trudsholm Godser....

Are Series A radically growing?

25/02/2025

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Neumirna Therapeutics secures euro 20M in Series A financing

08/01/2025

Neumirna Therapeutics secures euro 20M in Series A financing Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round...

Saving Lives with Venture Capital

07/09/2024

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...